Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
United Therapeutic (UTHR)
United Therapeutic (UTHR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,293,126
  • Shares Outstanding, K 46,994
  • Annual Sales, $ 1,936 M
  • Annual Income, $ 727,300 K
  • 60-Month Beta 0.57
  • Price/Sales 5.82
  • Price/Cash Flow 14.09
  • Price/Book 1.98
Trade UTHR with:

Options Overview Details

View History
  • Implied Volatility 25.58% ( -0.13%)
  • Historical Volatility 19.04%
  • IV Percentile 29%
  • IV Rank 30.67%
  • IV High 37.54% on 05/02/23
  • IV Low 20.29% on 09/15/23
  • Put/Call Vol Ratio 2.00
  • Today's Volume 15
  • Volume Avg (30-Day) 188
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 3,876
  • Open Int (30-Day) 3,780

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 3.79
  • Number of Estimates 9
  • High Estimate 4.67
  • Low Estimate 2.97
  • Prior Year 2.67
  • Growth Rate Est. (year over year) +41.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
219.12 +10.20%
on 11/09/23
243.75 -0.94%
on 12/04/23
+13.29 (+5.82%)
since 11/06/23
3-Month
210.00 +14.99%
on 11/01/23
243.75 -0.94%
on 12/04/23
+18.11 (+8.11%)
since 09/06/23
52-Week
204.44 +18.11%
on 05/30/23
283.09 -14.70%
on 12/09/22
-35.13 (-12.70%)
since 12/06/22

Most Recent Stories

More News
United Therapeutics: Q3 Earnings Snapshot

United Therapeutics: Q3 Earnings Snapshot

UTHR : 241.86 (+0.65%)
4 Promising Biotech Stocks for Smart Investment Strategies

The biotechnology industry is flourishing due to the recent strides in drug formulation, technological advancements, and unwavering government support. Given this backdrop, promising biotech stocks United...

GILD : 79.55 (+0.67%)
JAZZ : 121.90 (+0.34%)
UTHR : 241.86 (+0.65%)
VRTX : 352.33 (-0.51%)
How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success....

AMGN : 270.39 (-0.18%)
BIIB : 234.45 (+2.13%)
GILD : 79.55 (+0.67%)
REGN : 838.82 (+2.18%)
UTHR : 241.86 (+0.65%)
3 Biotech Stocks Showing Promising Returns for October

Technological advancements and the growing investment in developing healthcare infrastructures are expected to boost the biotech industry. Therefore, it could be wise to buy fundamentally strong biotech...

BMRN : 93.81 (+0.21%)
HALO : 40.27 (+0.93%)
UTHR : 241.86 (+0.65%)
Unlocking Biotech's Potential With 3 Stocks to Buy

The biotech industry’s growth is propelled by strong demand for medical support and interventions, favorable government initiatives, and rapid adoption of emerging technologies. Given the industry’s...

CORT : 26.72 (+0.98%)
SGIOY : 11.9400 (+1.62%)
UTHR : 241.86 (+0.65%)
3 Biotech Stocks to Buy for August

The biotechnology sector has experienced extraordinary expansion, largely due to technological advancements that continue to position the industry as a pioneering influencer in crucial areas of healthcare,...

GILD : 79.55 (+0.67%)
REGN : 838.82 (+2.18%)
UTHR : 241.86 (+0.65%)
Markets Today: Stocks Fall as Fitch Cuts its U.S. Debt Rating

Morning Markets September E-Mini S&P 500 futures (ESU2 3) this morning are down -0.61%, and Sep Nasdaq 100 E-Mini futures (NQU2 3) are down -0.88%. Stock indexes this morning are lower after Fitch Ratings’...

ESZ23 : 4,571.00 (-0.09%)
NQZ23 : 15,874.50 (-0.22%)
GNRC : 125.78 (+2.45%)
PINS : 34.03 (-0.23%)
SBUX : 96.55 (+1.06%)
CCL : 17.60 (+6.67%)
EA : 136.38 (-0.76%)
CWH : 22.46 (+2.79%)
NCLH : 18.57 (+5.57%)
VFC : 18.67 (+3.32%)
CVS : 73.36 (+3.29%)
ELF : 127.17 (+1.04%)
United Therapeutics: Q2 Earnings Snapshot

United Therapeutics: Q2 Earnings Snapshot

UTHR : 241.86 (+0.65%)
3 Biotech Stocks With 'A' POWR Ratings

The biotech industry is poised for significant growth due to the rising orphan drug formulations and the adoption of emerging technologies. Therefore, fundamentally strong biotech stocks Vertex Pharmaceuticals...

CRSP : 72.79 (+3.10%)
REGN : 838.82 (+2.18%)
UTHR : 241.86 (+0.65%)
VRTX : 352.33 (-0.51%)
4 Best Biotech Stocks According to POWR Ratings

Rapid advancements and soaring demand make the biotech sector well-positioned to witness significant growth in the foreseeable future. Given this backdrop, quality biotech stocks Amgen Inc. (AMGN), Regeneron...

AMGN : 270.39 (-0.18%)
REGN : 838.82 (+2.18%)
UTHR : 241.86 (+0.65%)
VNDA : 4.07 (+2.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by...

See More

Key Turning Points

3rd Resistance Point 246.51
2nd Resistance Point 243.77
1st Resistance Point 242.04
Last Price 241.86
1st Support Level 237.57
2nd Support Level 234.83
3rd Support Level 233.10

See More

52-Week High 283.09
Fibonacci 61.8% 253.05
Fibonacci 50% 243.76
Last Price 241.86
Fibonacci 38.2% 234.48
52-Week Low 204.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar